CR20150077A - Composición farmacéutica oral en forma de microesferas y proceso de elaboración - Google Patents

Composición farmacéutica oral en forma de microesferas y proceso de elaboración

Info

Publication number
CR20150077A
CR20150077A CR20150077A CR20150077A CR20150077A CR 20150077 A CR20150077 A CR 20150077A CR 20150077 A CR20150077 A CR 20150077A CR 20150077 A CR20150077 A CR 20150077A CR 20150077 A CR20150077 A CR 20150077A
Authority
CR
Costa Rica
Prior art keywords
microspheres
pharmaceutical composition
oral pharmaceutical
elaboration process
elaboration
Prior art date
Application number
CR20150077A
Other languages
English (en)
Inventor
Hernández Gustavo Barranco
Guiza María Del Coral Luna
Arroyo Héctor Senosiain
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50435594&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150077(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Publication of CR20150077A publication Critical patent/CR20150077A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición en forma de micropartículas que constanprincipalmente de: a) un núcleo inerte; b) una capa deprincipio activo formada por aspersión sobre el núcleoinerte y c) opcionalmente un segundo recubrimiento quecomprende una o más capas de fármaco(s) y/o excipiente(s)farmacéuticamente aceptable(s).
CR20150077A 2012-08-17 2015-02-13 Composición farmacéutica oral en forma de microesferas y proceso de elaboración CR20150077A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2012009583A MX351059B (es) 2012-08-17 2012-08-17 Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion.
PCT/IB2013/056690 WO2014027334A2 (es) 2012-08-17 2013-08-16 Composicion farmacéutica oral en forma de microesferas y proceso de elaboración

Publications (1)

Publication Number Publication Date
CR20150077A true CR20150077A (es) 2015-05-13

Family

ID=50435594

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150077A CR20150077A (es) 2012-08-17 2015-02-13 Composición farmacéutica oral en forma de microesferas y proceso de elaboración

Country Status (8)

Country Link
CL (1) CL2015000375A1 (es)
CO (1) CO7310526A2 (es)
CR (1) CR20150077A (es)
DO (1) DOP2015000028A (es)
GT (1) GT201500035A (es)
MX (1) MX351059B (es)
PE (1) PE20150710A1 (es)
WO (1) WO2014027334A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2978859B1 (en) 2013-03-27 2018-06-27 F.Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy
MX2017000582A (es) 2014-07-30 2017-04-27 Hoffmann La Roche Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl).
CN104523710B (zh) * 2014-12-30 2018-05-25 石药集团欧意药业有限公司 一种硫酸氢氯吡格雷阿司匹林复合双层片及其制备方法
KR101710441B1 (ko) * 2015-12-28 2017-02-28 신풍제약주식회사 안정성 및 용출성이 향상된 정제
EP3582777A4 (en) 2017-02-17 2020-12-23 Unichem Laboratories Ltd PHARMACEUTICAL COMPOSITION OF APIXABAN
CN106821996A (zh) * 2017-03-01 2017-06-13 华益药业科技(安徽)有限公司 马来酸依那普利颗粒剂及其制备方法
BR112020020941A2 (pt) * 2018-04-16 2021-03-02 Bristol-Myers Squibb Company formulações apixaban
WO2021168043A1 (en) * 2020-02-19 2021-08-26 Nano Pharmasolutions, Inc. Therapeutic agent nanoparticles and methods of preparation
US11833133B2 (en) * 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition
CN113413364A (zh) * 2021-05-31 2021-09-21 辰欣药业股份有限公司 一种依诺肝素钠注射液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007208998A1 (en) * 2006-01-27 2007-08-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A method of producing porous microparticles
MXPA06010972A (es) * 2006-09-25 2009-04-17 World Trade Imp Export Wtie Ag Proceso para estabilizacion de famotidina.
WO2008045006A1 (en) * 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
MX2007008440A (es) * 2007-07-11 2009-02-18 Senosiain S A De C V Lab Composicion farmaceutica combinada.

Also Published As

Publication number Publication date
GT201500035A (es) 2017-10-24
WO2014027334A3 (es) 2014-04-10
DOP2015000028A (es) 2015-03-15
PE20150710A1 (es) 2015-05-28
MX351059B (es) 2017-09-29
WO2014027334A2 (es) 2014-02-20
MX2012009583A (es) 2014-02-26
CL2015000375A1 (es) 2015-07-10
CO7310526A2 (es) 2015-06-30

Similar Documents

Publication Publication Date Title
CR20150077A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
CY1120783T1 (el) Ανθεκτικη εναντι παραβιασης και ανθεκτικη εναντι μεταποθηκευσης δοσης φαρμακευτικη μορφη δοσολογιας
CL2013000424A1 (es) Forma de dosificacion farmaceutica resistente al rompimiento que comprende a) un ingrediente farmacologicamente activo, b) un polimero, c) un oxido de polialquileno, donde a) esta presente en una matriz de liberacion controlada que comprende b) y c).
CL2014002754A1 (es) Forma de dosis de liberación controlada solida que comprende un nucleo con una primera porcion de un analgesico opioide y una cubierta que encierra el nucleo y comprende una segunda porcion del analgesico opioide; metodo de preparacion; uso en el tratamiento del dolor. (divisional de solicitud n°1450-2014).
CL2013002504A1 (es) Preparacion farmaceutica solida recubierta que comprende a lo menos un ingrediente activo y porque el recubrimiento tiene un espesor de 0,1 a 100nm, de preferencia de 0,3 a 50 nm y mas preferentemente de 0,5 a 35 nm; y su metodo de preparacion
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
FI20145771L (fi) Parasitisidaalisia oraalisia eläinlääkekoostumuksia, jotka käsittävät systeemisesti vaikuttavan aktiiviaineen, menetelmiä ja käyttöjä
AR096439A1 (es) Forma de dosificación resistente al uso indebido que contiene una o más partículas
CL2014000904A1 (es) Forma de dosis farmaceutica oral resistente a la ruptura que comprende i) un ingrediente farmacologicamente activo, ii) un antagonista opioide y/o un agente repelente, iii) un oxido de polialquileno y iv) un polimero anionico.
CR20140487A (es) Peliculas de capas multiples capaces de liberar ingredientes activos por un periodo limitado de tiempo
BR112014012005A2 (pt) composições, métodos, formulação farmacêutica e artigo
CL2014001016A1 (es) Compuestos triciclicos condensados y sus sales farmaceuticamente aceptables; composicion farmaceutica que los comprende; y su uso en el tratamiento de una infeccion viral.
CL2013003650A1 (es) Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo anti leucocidina luke y un portador farmaceuticamente aceptable.
CR20160067A (es) Comprimido farmacéutico que comprende ácido acetilsalicílico y clopidogrel
BR112013030472A2 (pt) formulação farmacêutica, artigo de fabricação e método
SMT201500126B (it) Nuova composizione farmaceutica resistente all'abuso per il trattamento di una dipendenza da oppioidi
WO2011140446A3 (en) Pharmaceutical formulations
CL2013003229A1 (es) Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc.
CO2017006898A2 (es) Formulación de relación fija de insulina glargina/lixisenatida
EP3481381A4 (en) ORAL PHARMACEUTICAL FORM WITH ACTIVE COMPOSITION, BARRIER AND ACTIVE LAYER
CL2014002988A1 (es) Procedimiento de fabricación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo.
CL2013003700A1 (es) Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.
CR20140540A (es) Nueva forma de dosificación y formulación de abediterol
AR092356A1 (es) Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion
GT201400042A (es) Compuesto de benzotiazolona